Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women

References

• Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biocbem Mol Biol 2001;76:231–8
   PubMed Web of Science ®Google Scholar
• Ederveen AGH, Kloosterboer HJ. Tibolone exerts its protective effect on trabecular bone loss through the estrogen receptor. J Bone Miner Res 2001;16:1651–7
   PubMed Web of Science ®Google Scholar
• Markiewicz L, Gurpride E. In vitro evaluation of estrogenic, estrogen antagonistic and progesto-genic effects of a steroidal drug (Org 0D14) and its metabolites on human endometrium. J Steroid Biocbem 1990;35:535–41
   PubMedGoogle Scholar
• Volker W, Coelingh Bennink HJT, Helmond FA. Effects of tibolone on the endometrium. Climac-teric 2001;4:203–8
   PubMedGoogle Scholar
• Hammar M, Christau S, Nathorst-Boos J, Rud T, Garre K. A double-blind randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in post-menopausal women with menopausal symptoms. Br J Obstet Gynaecol 1998;105:904–11
   Google Scholar
• Morris EP, Wilson PO, Robinson J, Rymer JM. Long-term effects of tibolone on the genital tract in postmenopausal women. Br J Obstet Gynae col 1999;106:954–9
   PubMed Web of Science ®Google Scholar
• Hahn RG. Compliance considerations with estrogen replacement: withdrawal bleeding and other factors. Am J Obstet Gynecol 1989;161: 1854–7
   PubMed Web of Science ®Google Scholar
• Coope J, Marsh J. Can we improve compliance with long-term HRT? Maturitas 1992;15:151–8
   PubMed Web of Science ®Google Scholar
• Gompel A, Kandouz M, Siromachkova M, et al. The effect of tibolone on proliferation, differen-tiation and apoptosis in normal breast cells. Gynecol Endocrinol 1997;11(Suppl 1):77–9
   Google Scholar
• Lippert C, Seeger H, Wallwiener D, Mueck AO. Tibolone versus 170-estradiol/norethisterone: effects on the proliferation of human breast cancer cells. Eur J Gynaecol Oncol 2002;23: 127–30
   PubMed Web of Science ®Google Scholar
• Ginsburg J, Prelevic G, Butler D, Okolo S. Clinical experience with tibolone (Livial) over 8 years. Maturitas 1995;21:71–6
   PubMed Web of Science ®Google Scholar
• Lundstrom E, Christow A, Svane G, et al. Effects of tibolone and a continuous combined HRT regimen on mammographic breast density. Am J Obstet Gynecol 2002;186:717–22
   PubMed Web of Science ®Google Scholar
• Rymer J, Chapman MG, Fogelman I. Effect of tibolone on postmenopausal bone loss. Osteo-poros Int 1994;4:314–19
   PubMed Web of Science ®Google Scholar
• Rymer J, Robinson J, Fogelman I. Effects of 8 years of treatment with tibolone 2.5 mg daily on postmenopausal bone loss. Osteoporos Int 2001;12: 478–83
   Google Scholar
• Chopra A. Osteoporosis: a new understanding of its impact and pathogenesis. J Am Osteopath Assoc 2000;100(Suppl):S1— S4
   Google Scholar
• Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 1993;341:72–5
   PubMed Web of Science ®Google Scholar
• Melton LJ III, Atkinson EJ, O'Fallon WM, Wahner I-IW, Riggs BL. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 1993;8:1227–33
   Google Scholar
• Gallagher JC, Baylink DJ, Freeman R, McClungM. Prevention of bone loss with tibolone in postmenopausal women: results of two random-ized, double-blind, placebo-controlled, dose-finding studies. J Gun Endocrinol Me tab 2001;86:4717–26
   PubMed Web of Science ®Google Scholar
• Milner M, Harrison RF, Gilligan E, Kelly A. Bone density changes during 2 years' treatment with tibolone or conjugated estrogens and norgestrel, compared with untreated controls in postmeno-pausal women. Menopause 2000;7:327–33
   PubMed Web of Science ®Google Scholar
• Thiebaud D, Bigler JM, Renteria S, et al. A 3-year study of prevention of postmenopausal bone loss: conjugated equine estrogens plus medroxy-progesterone acetate versus tibolone. Climacteric 1998;1:202–10
   PubMedGoogle Scholar
• Bjarnason NH, Bjarnason K, Haarbo J, Rosenquist C, Christiansen C. Tibolone: preven-tion of bone loss in late postmenopausal women. J Gun Endocrinol Metab 1996;81:2419–22
   Google Scholar
• Bjarnason NH, Bjarnason K, Hassager C, Christiansen C. The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women. Bone 1997;20:151–5
   PubMed Web of Science ®Google Scholar
• Geusens P, Dequeker J, Gielen J, Schot LPC. Non-linear increase in vertebral density induced by a synthetic steroid (Org OD14) in women with established osteoporosis. Maturitas 1991;13: 155–62
   PubMed Web of Science ®Google Scholar
• Studd J, Arnala I, Kicovic PM, Zamblera D, Kroger H, Holland N. A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures. Obstet Gynecol 1998;92:574–9
   PubMed Web of Science ®Google Scholar
• Egarter C, Sator M, Berghammer P, Huber J. Efficacy, tolerability and rare side effects of tibolone treatment in postmenopausal women. Int J Gynecol Obstet 1999;64:281–6
   PubMed Web of Science ®Google Scholar
• Rymer J, Chapman MG, Fogelman I. A study of the effect of tibolone on the vagina in post-menopausal women. Maturitas 1994;18:127–33
   Google Scholar
• Gompel A, Siromachkova M, Lombet A, Kloosterboer HJ, Rostene W. Tibolone actions on normal and breast cancer cells. Eur J Cancer 2000;36(Suppl 4):576–7
   Google Scholar
• Doren M, Riibig A, Coelingh Bennink HJT, Holzgreve W. Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethis-terone acetate replacement therapy. Menopause 1999;6:299–306
   PubMed Web of Science ®Google Scholar
• Huber J, Palacios S, Berglund L, et al. The effect of tibolone compared with conjugated equine oestrogens continuously combined with medroxyprogesterone acetate on bleeding rates, quality of life and tolerability in postmenopausal women. Br J Obstet Gynaeco/ 2002;109:886–93
   PubMed Web of Science ®Google Scholar
• Valdivia I, Ortega D. Mammographic density in postmenopausal women treated with tibolone, estriol or conventional hormone replacement therapy. Clin Drug Invest 2000;20:101–7
   PubMed Web of Science ®Google Scholar
• Colacurci N, Fornaro F, de Franciscis P, Palermo M, del Vecchio E. Effects of different types of hormone replacement therapy on mammo-graphic density. Maturitas 2001;40:159–64
   Google Scholar
• Erel CT, Esen G, Seyisoglu H, et al. Mammo-graphic density increase in women receiving different hormone replacement regimens. Maturitas 2001;40:151–7
   PubMed Web of Science ®Google Scholar
• Tax L, Goorissen EM, Kicovic PM. Clinical profile of Org 0D14. Maturitas 1987;Suppl 1: 3–13
   Google Scholar
• Genazzani AR, Petraglia F, Facchinetti F, et al. Effects of Org 0D14 on pituitary and peripheral 0-endorphin in castrated rats and in postmeno-pausal women. Maturitas 1987;Suppl 1:35–48
   Google Scholar